Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs. The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice.
The global RWE solutions market is projected to reach USD 2.3 billion by 2026 from USD 1.2 billion in 2021, at a CAGR of 14.4% during the forecast period. The rising geriatric population (and the subsequent increase in the prevalence of chronic diseases) is a key factor driving the growth of this market. The shift from volume- to value-based care, delays in drug development (and the subsequent increase in development costs), growth in R&D spending, and support from regulatory bodies for the use of RWE solutions are some of the other major factors that are driving the growth of this market. However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection are restraining the growth of this market.
To know about the assumptions considered for the study download the pdf brochure
The prominent players in the RWE solutions market are IQVIA (US), IBM Corporation (US), ICON plc. (Ireland), PAREXEL International Corporation (US), PPD, LLC (US), Optum, Inc. (US), Cognizant Technology Solutions Corporation (US), Oracle Corporation (US), SAS Institute Inc. (US), Syneos Health, Inc. (US), Anthem, Inc. (US), Clinigen Group plc. (UK), Medpace Holdings Inc. (US) and Flatiron Health, Inc. (US). These companies adopted strategies such as service launches, business expansions, agreements, partnerships, collaborations, and acquisitions to strengthen their presence in the RWE solutions market.
IQVIA
IQVIA is the leading player in the RWE solutions market. The company is a global provider of RWE solutions with wide geographical coverage. The leading position of IQVIA in the market is attributed to various factors, such as its robust technical and service capabilities, good client relationships, diversified service offerings, and its ability to enhance the penetration of its offerings. IQVIA focuses on product launches and agreements & partnerships to sustain its market position. The company has a wide geographical presence in ~100 countries across North America, Europe, Asia, Latin America, and Africa.
ICON PLC
ICON Plc is the second-leading player in this market. The company offers drug development and clinical, consulting, and commercial services (ranging from trial design to post-market commercialization services) across the globe. The company mainly focuses on product launches and acquisitions to maintain its leading position in the RWE solutions market. ICON has a global presence, covering the US, Ireland, the Rest of Europe, Canada, Argentina, Brazil, Chile, Colombia, Mexico, Peru, China (including Hong Kong), India, Israel, Japan, Singapore, South Korea, the Philippines, Taiwan, Thailand, Australia, New Zealand, and South Africa. The company’s extensive R&D activities for new product development will drive further growth in innovation in the long term.
Related Reports:
Real World Evidence/RWE Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Neurology), End User (Pharma, Medtech, Payers, Providers) Covid-19 Impact - Global Forecast to 2026
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]